The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
 
Amod Sarnaik
No Relationships to Disclose
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Bellicum Pharmaceuticals; Mazor Robotics; Transenterix
Honoraria - Bristol-Myers Squibb; Sanofi
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; HUYA Bioscience International; Immunocore; Incyte; Merck; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Jason Alan Chesney
Consulting or Advisory Role - Amgen; Replimune
Research Funding - Amgen; Iovance Biotherapeutics; Replimune
 
Karl D. Lewis
Honoraria - Array BioPharma
Consulting or Advisory Role - Array BioPharma; Merck; Regeneron; Roche
Research Funding - alkermes (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Theresa Michelle Medina
No Relationships to Disclose
 
Harriet M. Kluger
Consulting or Advisory Role - Array BioPharma; Biodesix; Celldex; Corvus Pharmaceuticals; Genentech/Roche; Immunocore; Iovance Biotherapeutics; Merck; Nektar; Pfizer
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
Sajeve Samuel Thomas
No Relationships to Disclose
 
Evidio Domingo Musibay
Honoraria - Regeneron
Consulting or Advisory Role - Immunocore; Sanofi/Regeneron
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst); Prometheus (Inst)
 
Anna C. Pavlick
No Relationships to Disclose
 
Eric D. Whitman
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Novartis; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Dynavax Technologies (Inst); Genentech/Roche (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); Oncolys BioPharma (Inst); OncoSec (Inst); Provectus (Inst); Toray Industries (Inst); Toray Industries (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Lighted Polyhedral surgical retractor; Nerve monitoring dissection device
 
Salvador Martin-Algarra
No Relationships to Disclose
 
Philippa Gail Corrie
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Halozyme (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Jose Lutzky
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis
Speakers' Bureau - Array BioPharma; Novartis; Regeneron
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Elios Pharmaceutical (Inst); Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Omid Hamid
Honoraria - Array BioPharma; Bristol-Myers Squibb; Novartis; Sanofi/Regeneron
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Amgen; Array BioPharma; BeiGene; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Immunocore; Incyte; Janssen; Merck; NextCure; Novartis; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna
Speakers' Bureau - Array BioPharma; Bristol-Myers Squibb; Novartis; Sanofi/Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Renee Wu
No Relationships to Disclose
 
Wen Shi
No Relationships to Disclose
 
Maria Fardis
Employment - Iovance Biotherapeutics
Leadership - Iovance Biotherapeutics
Stock and Other Ownership Interests - Abbvie/Pharmacyclics; Gilead Sciences; Iovance Biotherapeutics
Speakers' Bureau - Iovance Biotherapeutics
Patents, Royalties, Other Intellectual Property - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
Other Relationship - Kartos Therapeutics
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; CytomX Therapeutics; Protean Biodiagnostics
Honoraria - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Nektar; Novartis; Oncorus; Protean Biodiagnostics; Roche; Sellas Life Sciences; Takeda Science Foundation; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Merck; Novartis; Roche; Takeda
 
James M. G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Amgen (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Elsevier; Immunocore; Immunocore (Inst); Iovance Biotherapeutics; Merck (Inst); Novartis
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst)